Grading Systems Proposed to Improve the Precision of Treatment for MTC
The movement to adopt a grading system for MTC is the result of years of research and is intended to make the care of patients with MTC more precise.
MTC Insights
The Evolution of Our Understanding of Medullary Thyroid Carcinoma
We look at how our understanding of medullary thyroid carcinoma has evolved over the last several decades, and what we now know about treating the cancer.
Understanding the Geographic Differences of RET Mutations in MTC
We take a look at epidemiological data on the global distribution of RET mutations in cases of medullary thyroid carcinoma.
AATD Insights, CAD Insights, DMD Insights, Insights, LAL-D Insights, LCFAOD Insights, MG Insights, MTC Insights, SCD Insights
The Far-Reaching Impact of Innovative Clinical Trial Designs in Rare Disease
We examine the lasting impact of innovative clinical trial designs for rare diseases on other clinical experiments.
Case Study: Metastatic MTC Presenting as Cushing’s Syndrome in a 41-Year-Old Man
We discuss the case study of a patient who was diagnosed with medullary thyroid carcinoma with paraneoplastic Cushing‘s syndrome.
Targeting the PDGF/PDGFR Pathway in Cancer Research
We discuss current therapeutic strategies in targeting the PDGF/PDGFR signaling pathway in cancer research.
Thyroid Collision Tumors: Extremely Rare and Challenging to Treat
We describe the characteristics of exceedingly rare thyroid collision tumors and look at a real-world case study.
Understanding the Prognosis of MTC Patients With Lymph Node Metastases
We discuss studies investigating the prognosis of MTC patients with lymph node metastases, as well as the best way to break bad news to patients.
The Role of CCK2R in Nuclear Imaging for Medullary Thyroid Carcinoma
We examine the role of the cholecystokinin-2 receptor (CCK2R) in MTC nuclear imaging, and discuss methods of targeting it more efficiently.
Exploring TKI-Induced Nephrotoxicity in Patients With Medullary Thyroid Carcinoma
We explore various issues related to nephrotoxicity induced by tyrosine kinase inhibitors in patients with medullary thyroid carcinoma.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in MTC Insights
Loading... 
Loading...